WaveMan
WaveMan · Company
AKTX · Akari Therapeutics Plc
> Search tickers & screens ⌘K
LIVE
← All companies

AKTX Akari Therapeutics (AKTX) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Pharmaceutical preparations · CIK 0001541157
Quote by TradingView
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
6
13F, latest reported quarter
Conversions, 180 days
9
Codes C/M, not in net · $9.7K priced

Akari Therapeutics insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

No insider purchases or sales are on record for Akari Therapeutics Plc in the period covered. Source: SEC Form 4 filings, as of 2026-10-28.

Insider
Filed
Shares
Value
Since filing
Gaslightwala Abizer
CEO
BUY
2025-08-29 SECtraded 2025-08-25
3,000
$2.7K
-69.4%
Context
  • 6 earlier Form 4 trades (code P or S) here by this insider (6 buys), the last on Aug 22, 2025.
  • -31.8% median (-36.3% mean) 90-day return after 6 previous buys.
  • The trade is 1.0% of the 298,574 shares held after it.
  • No other insider bought within 30 days.
  • 6 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: CEO Gaslightwala Abizer bought about $2.7K of AKTX on Aug 25, 2025; 6 funds added in the latest 13F quarter.
Gaslightwala Abizer
CEO
BUY
2025-08-29 SECtraded 2025-08-22
8,000
$7.4K
-69.4%
Context
  • 5 earlier Form 4 trades (code P or S) here by this insider (5 buys), the last on Aug 21, 2025.
  • -29.4% median (-33.5% mean) 90-day return after 5 previous buys.
  • The trade is 2.7% of the 295,574 shares held after it.
  • No other insider bought within 30 days.
  • 6 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: CEO Gaslightwala Abizer bought about $7.4K of AKTX on Aug 22, 2025; 6 funds added in the latest 13F quarter.
Gaslightwala Abizer
CEO
BUY
2025-08-29 SECtraded 2025-08-21
10,000
$9.4K
-69.4%
Context
  • 4 earlier Form 4 trades (code P or S) here by this insider (4 buys), the last on Jun 24, 2025.
  • -29.4% median (-30.4% mean) 90-day return after 4 previous buys.
  • The trade is 3.5% of the 287,574 shares held after it.
  • No other insider bought within 30 days.
  • 6 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: CEO Gaslightwala Abizer bought about $9.4K of AKTX on Aug 21, 2025; 6 funds added in the latest 13F quarter.
Gaslightwala Abizer
President & CEO
BUY
2025-06-25 SECtraded 2025-06-24
5,203
$6.0K
-81.7%
Context
  • 3 earlier Form 4 trades (code P or S) here by this insider (3 buys), the last on Jun 23, 2025.
  • -29.4% median (-30.7% mean) 90-day return after 3 previous buys.
  • The trade is 1.9% of the 277,574 shares held after it.
  • No other insider bought within 30 days.
  • 6 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: President & CEO Gaslightwala Abizer bought about $6.0K of AKTX on Jun 24, 2025; 6 funds added in the latest 13F quarter.
Gaslightwala Abizer
President & CEO
BUY
2025-06-25 SECtraded 2025-06-23
943
$1.1K
-81.7%
Context
  • 2 earlier Form 4 trades (code P or S) here by this insider (2 buys), the last on Jun 20, 2025.
  • -31.4% median (-31.4% mean) 90-day return after 2 previous buys.
  • The trade is 0.3% of the 272,371 shares held after it.
  • No other insider bought within 30 days.
  • 6 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: President & CEO Gaslightwala Abizer bought about $1.1K of AKTX on Jun 23, 2025; 6 funds added in the latest 13F quarter.
7 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 2 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
no insider buys or sells on file
Congress
no House purchase disclosed in the last 12 months
Funds
6 funds bought in last quarter
below 92% of Pharma & Biotech
Revenue
-39.5% year over year
below 76% of Pharma & Biotech
Margin
no margin: no revenue reported
Buybacks
no share repurchases reported
Short interest
1.2% of the float short (float per yahoo 2026-10-27) · 1.0 days to cover · settled 2026-10-15
the lowest in Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days

Watch AKTX

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-71.0%12M
-90%-56%-23%+11%2025-102025-122026-022026-042026-062026-082026-10
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns AKTX: institutional holders (13F)

13F holdings, latest reported quarter
MMCAP International Inc. SPC
100,000 sh
$1.0M
Cresset Asset Management, LLC
20,561 sh
$210.6K
JANE STREET GROUP, LLC
15,463 sh
$158.4K
IFP Advisors, Inc
181 sh
$1.9K
SBI Securities Co., Ltd.
14 sh
$143

Congress trades in AKTX

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

AKTX planned insider sales (Form 144)

No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
Clinical pipeline
8 registered trials, 0 still running (ClinicalTrials.gov). A status change is dated here weeks before the press release.
3
Phase 2
0 active
4
Phase 3
0 active
1
Multi-phase
0 active
Matched by sponsor name. Trials run under a subsidiary's own name are not included.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows 6 funds added last quarter. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

AKTX financials

Revenue growth
-39.5%
XBRL, annual
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
n/a
fewer than four consecutive quarters of revenue filed
Net margin, TTM
n/a
needs four consecutive quarters of both revenue and net income
Free cash flow, TTM
n/a
capex not filed for the four quarters
Debt to equity
0.01x
current debt only, 2024-09-30 (21 months older than the period end); equity 2026-06-30
Cash flow to debt
-53.80x
TTM operating cash flow over current debt only, 2024-09-30 (21 months older than the period end)
Return on equity
-140.1%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
-69.2%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
pre-tax loss, no effective tax rate to apply
Return on capital employed
-106.0%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
$1.3T
market value at close 2026-10-27 on 2026-08-13 shares, plus current debt only, 2024-09-30 (21 months older than the period end), minus cash 2026-06-30
FCF yield
n/a
capex not filed for the four quarters
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-10-27. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Revenuen/an/a$367.9K$607.7K
Operating income-$17.3M-$21.6M-$16.8M-$11.8M
Net income-$17.3M-$19.8M-$10.0M-$13.1M
EPS (diluted)0.000.000.00-0.74
Operating cash flow-$10.6M-$12.6M-$16.4M-$7.5M
Cash$5.2M$0$3.8M$654.9K
SEC XBRL, fiscal years, as known on 2026-10-28

AKTX Stock Sonar score 5/7 axes

Find similar shapesCompare

AKTX ranks highest on risk and compliance (87th percentile) and financial health (44th), and lowest on institutional and government (8th), among Pharma & Biotech peers.

ProfitHealthGrowthInstitutionsRisk
Profitability
28
Inputs
  • Return on equity-140.1% · 24 pct, sector of 545
  • Return on assets-69.2% · 35 pct, sector of 691
  • Return on invested capitalpre-tax loss, no effective tax rate to apply
  • Return on capital employed-106.0% · 24 pct, sector of 576
Financial health
44
Inputs
  • Debt to equity0.01x · 77 pct, sector of 352
  • Cash flow to debt-53.80x · 11 pct, sector of 371
Growth
24
Inputs
  • Revenue growth, YoY-39.5% · 24 pct, sector of 505
  • Backlog growth, YoYno backlog line filed, or no year-earlier backlog
Institutional and government
8
Inputs
  • Funds adding, latest quarter6 · 8 pct, sector of 698
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
87
Inputs
  • Short interest, % of float+1.2% · 78 pct, sector of 816
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-K+1.6% · 97 pct, sector of 511
2 not measured: Insider conviction, US patents
  • Insider conviction needs 1 of 2 inputs, 0 present: no Form 4 purchase or sale (code P or S) in 180 days; no insider trades in 180 days
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

5 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies